Slack may venture into healthcare

Slack, a messaging app for business, could be on the brink of venturing into the healthcare space. The company recently filed confidential initial public offering (IPO) papers with the SEC earlier this month and updated its security page to note HIPAA compliance, according to CNBC. 

Compliance with HIPPA, or the Health Insurance Portability and Accountability Act of 1996, ensures the privacy and protection of health information. The move sets up Slack to potentially upload and send health information.

The reports come at a time when other major technology companies, including Apple, continue to take larger steps into the healthcare sector through their products and services. 

“Slack Technologies, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 with the [SEC] relating to the proposed public listing of its Class A common stock,” read a prepared statement issued by the company. “The public listing is expected to take place after the SEC completes its review process, subject to market and other conditions.”

Many providers already use Slack for administrative matters that do not incorporate patient-sensitive information.

At present, the compliance only extends to file uploading and not for direct messages or communication between healthcare providers. However, Slack will expand its HIPPA-compliant scope to include messaging, sources who spoke to CNBC said.

To read the story, click the link below.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.